Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of GSK2982772 in Healthy Males
NCT02302404Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2015
- Primary completion
- Mar 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2982772 in inflammatory bowel disease (IBD) (7 cohorts), sponsored by GSK. Primary endpoints: Safety and tolerability of GSK2982772, Change in laboratory values and 3 more. Started Jan 2015; status: completed.
02
Drugs
GSK2982772
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02302404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302404.